IHL - INCANNEX - HOLDERS RESEARCH, page-414

Jazz Pharmaceuticals buying more sleep disorder candidates is big news for IHL.

This licensing agreement with Sumitomo Pharma is on a potential drug that’s only currently in Phase 1 trials.

Jazz are paying US$50 million as an upfront payment plus milestone payments of US$1.09 billion. This is just to license the product, not to own the IP.

And remember Jazz bought GW Pharma for US$7.4 billion to leverage Epidiolex, which is much smaller commercial opportunity than obstructive sleep apnea.

IHL-42X could easily be a US$10 billion transaction if you extrapolate even a modest penetration of the annual revenues that CPAP generates globally. Very exciting.

https://www.prnewswire.com/news-rel...oral-orexin-2-receptor-agonist-301537690.html